ArticleFrontiers in psychiatry2025
Atypical progression of delayed encephalopathy post-carbon monoxide poisoning with fluctuating psychotic symptoms: a case report.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This report details a case of delayed encephalopathy after acute carbon monoxide poisoning (DEACMP), a condition with significant neuropsychiatric sequelae that is often underrecognized. The case is notable for its atypical progression and poor response to conventional treatments, highlighting the need for awareness and novel approaches in managing similar cases. Case report: Mrs. C, a 53-year-old female with a long history of recurrent depression, suffered from severe carbon monoxide poisoning. Despite initial recovery, she exhibited a relapse marked by profound cognitive decline and erratic behaviors such as inappropriate urination and fecal smearing. The diagnostic workup, including MRI and neuropsychological testing, confirmed DEACMP. Various treatments were employed with limited success. Her course of illness underscores the fluctuating nature of her symptoms and the overall decline in her cognitive function. Conclusions: This case underscores the complex clinical management and refractory nature of DEACMP, emphasizing the necessity for comprehensive, individualized treatment approaches. The insights provided here advocate for heightened surveillance during the 'false recovery period' and tailored therapeutic strategies to alleviate symptoms, improve quality of life, and minimize long-term neurological damage in patients suffering from DEACMP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.